Naturally Splendid Responds to Health Canada’s Information Request Notice

Vancouver, British Columbia – TheNewswire – October 16, 2020 – Naturally Splendid Enterprises Ltd. (“Naturally Splendid”, “NSE” or “the Company”) (FRANKFURT:50N) (TSXV:NSP) (OTC:NSPDF) has responded through their joint venture Plasm Pharmaceutical (“Plasm”) to Health Canada’s Information Request Notice (“IRN”). The questions as posed by Health Canada are considered a formality as Plasm Pharmaceutical, continues to prepare for aContinue reading “Naturally Splendid Responds to Health Canada’s Information Request Notice”

Naturally Splendid Announces Inventory Produced for Target Drug, Cavaltinib(TM) for Phase 2 COVID 19 Clinical Trial

Vancouver, British Columbia – TheNewswire – June 1, 2020 – Naturally Splendid Enterprises Ltd. (“Naturally Splendid”, “NSE” or “the Company”) (FRANKFURT:50N) (TSXV:NSP) (OTC:NSPDF) is pleased to provide the following progress update for a Phase 2 clinical trial treatment for COVID 19. The Company is now awaiting notification by Health Canada to proceed to the Phase 2 clinical trial stage,Continue reading “Naturally Splendid Announces Inventory Produced for Target Drug, Cavaltinib(TM) for Phase 2 COVID 19 Clinical Trial”

Naturally Splendid Announces Clinical Trial Application Submitted to Health Canada for Phase 2 COVID 19 Clinical Trial

“The same study protocol is being prepared for submission to the U.S. FDA regulatory authorities.” Vancouver, British Columbia – TheNewswire – May 26, 2020 – Naturally Splendid Enterprises Ltd. (“Naturally Splendid”, “NSE” or “the Company”) (FRANKFURT:50N) (TSXV:NSP) (OTC:NSPDF) is pleased to provide the following update regarding progress for a Phase 2 clinical trial treatment for COVID 19. TheContinue reading “Naturally Splendid Announces Clinical Trial Application Submitted to Health Canada for Phase 2 COVID 19 Clinical Trial”

Naturally Splendid COVID-19 PHASE II Clinical Trial

Naturally Splendid CavaltinibTM for Covid-19, Phase II Clinical Trial Health Canada Application status update. Medical product CavaltinibTM so far is showing that it is a prospective contender for COVID-19 treatment, and possibly additional immune system and inflammatory conditions. Health Canada’s Office of Regulatory Affairs’ Biologic and Radiopharmaceutical Drugs Directorate approval is next for the CavaltinibTMafterContinue reading “Naturally Splendid COVID-19 PHASE II Clinical Trial”